tiprankstipranks
Trending News
More News >
Repligen (CH:RGN)
:RGN

Repligen (RGN) Price & Analysis

Compare
0 Followers

RGN Stock Chart & Stats

Currently, no data available
Please return soon. This page is being updated.

Bulls Say, Bears Say

Bulls Say
Financial GuidanceRepligen has favorably revised its top-line guidance for 2025 to a range of $695M to $720M, up from the prior $685-710M.
Revenue GrowthRepligen recorded 1Q25 revenue totaling $169.2M, slightly better than the original top-line forecast of $165M.
Bears Say
Market And Economic ConditionsUncertainty regarding current market and economic conditions, including tariff and Forex issues, is leading to a Hold rating on RGEN shares.
Net Earnings GuidanceRepligen expects full-year 2025 GAAP net earnings of $0.76 - $0.85 per diluted share, down from the original guidance range of $0.90 - $0.99 per diluted share.

Financials

Options Prices

Currently, No data available
---

Ownership Overview

0.72%37.22%2.95%37.75%
37.22%
Mutual Funds
2.95% Other Institutional Investors
37.75% Public Companies and Individual Investors

RGN FAQ

What was Repligen’s price range in the past 12 months?
Currently, no data Available
What is Repligen’s market cap?
Currently, no data Available
When is Repligen’s upcoming earnings report date?
Repligen’s upcoming earnings report date is Aug 05, 2025 which is in 59 days.
    How were Repligen’s earnings last quarter?
    Repligen released its earnings results on Apr 29, 2025. The company reported $0.32 earnings per share for the quarter, beating the consensus estimate of $0.284 by $0.036.
      Is Repligen overvalued?
      According to Wall Street analysts Repligen’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
        Does Repligen pay dividends?
        Repligen does not currently pay dividends.
        What is Repligen’s EPS estimate?
        Repligen’s EPS estimate is 0.32.
          How many shares outstanding does Repligen have?
          Currently, no data Available
          What happened to Repligen’s price movement after its last earnings report?
          Repligen reported an EPS of $0.32 in its last earnings report, beating expectations of $0.284. Following the earnings report the stock price went same N/A.
            Which hedge fund is a major shareholder of Repligen?
            Currently, no hedge funds are holding shares in CH:RGN

            Company Description

            Repligen

            Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

            RGN Earnings Call

            Q1 2025
            0:00 / 0:00
            Earnings Call Sentiment|Positive
            Repligen Corporation had a strong start to 2025 with notable achievements in revenue growth, strategic acquisitions, and product launches. However, there are challenges in specific segments such as capital equipment, China, and small biotech companies. Despite these challenges, the company's strategic initiatives and strong order performance indicate a positive outlook for the year.Read More>

            RGN Revenue Breakdown

            44.00%44.00%37.00%19.00%
            44.00% North America
            37.00% Europe
            19.00% APAC/Other
            tipranks

            RGN Stock 12 Month Forecast

            Average Price Target

            $148.49
            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
            Similar Stocks
            Company
            Price & Change
            Follow
            ICU Medical
            Masimo
            Merit Medical Systems
            Teleflex
            Stevanato Group
            Popular Stocks
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis